Unique challenges can affect the success of the shift from pediatric to adult care settings.
To close the discussion, experts on C. difficile infections discuss how they talk with patients about fecal microbiota transplantation.
Christine Slover, PharmD discussed cefiderocol's effectiveness against challenging infections, including those caused by multi-drug resistant bacteria.
Su H Wang, MD, FACP, MPH discusses combating vaccine misinformation, preventing outbreaks, and highlighting global health interconnectedness
Social media platforms, public health agencies, and communities must join forces to stop the rapid spread of false information.
With the addition of 2 new live biotherapeutic products, a clinician reviews the application, storage and administration techniques for them.
Findings increasingly suggest the mortality risk may be reduced by initiating daptomycin within 3 days of infection.
A study underscores the microbial etiology of septic arthritis, which can guide clinicians in minimizing the use of overly broad empiric antibiotics.
Examining pharmacological management in COVID-19 patients with ARDS requiring antifungal therapy during extracorporeal life support.
A pair of experts assess literature on the means of interpreting hospitalized patient antibiotic resistance through machine learning.
Study results show that the vaccine elicits a comparable immune response in high-risk adults aged 18-59 with chronic medical conditions, suggesting potential for broader vaccination efforts.
As the first line of acute care, emergency departments are key stewards of antibiotics.
Cornelius Clancy, MD, highlights the real-world outcomes of cefiderocol treatment for serious gram-negative bacterial infections, reporting a clinical success rate of 75% along with encouraging safety data.
Important clinical considerations to know about resistant CMV infections.
As the first line of acute care, emergency departments are key stewards of antibiotics.
Clinicians look at optimal approaches for trying to avoid Clostridioides difficile infection (CDI).
New therapeutics offer some hope in this emerging market.
The latest article from SIDP offers a Top 5 list of how to precept a learner on an infectious disease rotation.
There is limited and conflicting data regarding the role of combination antifungal therapy for treatment of invasive mucormycosis.
Clinicians review a patient case including diagnosis, treatment, and follow-up.
The prevalence of this disease in this patient population is much higher than in the general public.
In the latest column from SIDP, the authors discuss having leaders to help navigate school and beyond.
The limitation in the number of pediatric-specific guidelines by professional organizations, and results from large randomized clinical trials, may place an additional emphasis on literature evaluation skills for pediatric ASP pharmacists.
Experts share advice for physicians taking care of patients with C. difficile infection (CDI).
Drs Jacinda Abdul-Mutakabbir, Madeline King, Rodney Rohde, and expert nurse practitioner Wendy Wright provide insight on receiving the influenza vaccine concurrently with the SARS-CoV-2 booster shot, and comment on data on immune responses from the Moderna and Pfizer/BioNTech vaccines.
Research finds that individuals who received a COVID-19 vaccine more recently were less likely to develop long COVID.
Despite advances in understanding and treating Long COVID, many questions about its mechanisms, susceptibility, and varied recovery patterns remain unresolved, underscoring the need for continued research.
This market has seen a flurry of activity, as shown by a review of the latest agents.